TB-PRACTECAL
Short All-Oral Regimens for Rifampicin-Resistant TB
Patient / Population Intervention / Exposition Comparaison Critère de jugement
In 552 patients with rifampicin-resistant tuberculosis, a 24-week regimen of bedaquiline, pretomanid, linezolid and moxifloxacin improved favourable outcome at 72 weeks compared with the 9–20-month standard of care.
N
301
Schéma
Open-label RCT
Critère
Favourable outcome at 72 weeks
Pertinence
1
RésultatmITT: 89 % vs 52 % favourable (unfavourable 11 % vs 48 %; risk difference −37 pp, 96.6 % CI −53 to −22); noninferior, better safety with BPaLM.
Nyang'wa BT, et al. N Engl J Med. 2022;387(25):2331-2343. 10.1056/NEJMoa2117166
Discussion et critique
Generational shift in MDR-TB care: 6-month all-oral BPaLM replaces 18–24-month injectable-based regimens — now the WHO-preferred therapy for MDR-TB without fluoroquinolone resistance.